GlassScriptPhysician profile
Daniel A Hidaka
NPI 1215190764
$673.80
in general payments reported to CMS, 2019-2025
19 companies · $60.00 in 2025
The $60.00 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $15.88 · 2021: $21.93 · 2022: $79.52 · 2023: $16.52 · 2025: $60.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $76.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $76.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $100.25 | 2019-2022 | |
| Novo Nordisk INC | $69.97 | 2019-2022 | |
| Lilly USA, LLC | $63.45 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.68 | 2019-2023 | Trulance, Xifaxan |
| Astrazeneca Pharmaceuticals LP | $50.77 | 2019-2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $46.91 | 2019-2022 | |
| Alk-Abello, INC | $38.73 | 2019 | |
| Pfizer INC. | $34.89 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.80 | 2019 | |
| Phathom Pharmaceuticals, INC. | $26.43 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.35 | 2019 | |
| Abbvie INC. | $21.93 | 2021 | |
| Glaxosmithkline, LLC. | $18.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.00 | 2019 | |
| Radius Health, INC. | $17.44 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.14 | 2019 | |
| Merck Sharp & Dohme LLC | $16.50 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hidaka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.